Isis Pharmaceuticals Stock Downgraded (ISIS)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Isis Pharmaceuticals (Nasdaq: ISIS) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, generally high debt management risk, disappointing return on equity and generally disappointing historical performance in the stock itself.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • ISIS PHARMACEUTICALS INC's earnings per share declined by 37.0% in the most recent quarter compared to the same quarter a year ago. Earnings per share have declined over the last two years. We anticipate that this should continue in the coming year. During the past fiscal year, ISIS PHARMACEUTICALS INC reported poor results of -$0.85 versus -$0.62 in the prior year. For the next year, the market is expecting a contraction of 1.2% in earnings (-$0.86 versus -$0.85).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 40.0% when compared to the same quarter one year ago, falling from -$26.88 million to -$37.64 million.
  • The debt-to-equity ratio of 1.30 is relatively high when compared with the industry average, suggesting a need for better debt level management.
  • Current return on equity is lower than its ROE from the same quarter one year prior. This is a clear sign of weakness within the company. Compared to other companies in the Biotechnology industry and the overall market, ISIS PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • In its most recent trading session, ISIS has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
.

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using antisense drug discovery platform. Its product pipeline comprises 26 drugs to primarily treat cardiovascular, metabolic, severe, and rare diseases, as well as cancer. The company has a P/E ratio of -12.1, below the S&P 500 P/E ratio of 17.7. Isis has a market cap of $877.3 million and is part of the health care sector and drugs industry. Shares are up 12.2% year to date as of the close of trading on Wednesday.

You can view the full Isis Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Isis Pharmaceuticals Changes Its Name

Isis Pharmaceuticals Changes Its Name

Highlighted Post-Market Laggard: ISIS Pharmaceuticals (ISIS)

Jim Cramer's 'Mad Money' Recap: Stocks Gain When Analysts Curb Negativity

ISIS Pharmaceuticals (ISIS) Weak On High Volume